Absci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal Health
Portfolio Pulse from
Absci and Invetx have partnered to utilize Absci's generative AI Drug Creation models to develop a novel antibody Half-Life Extension platform for animal health applications.
January 06, 2025 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Absci has partnered with Invetx to apply its generative AI Drug Creation models in developing a new antibody platform for animal health, potentially expanding its market reach.
The partnership with Invetx allows Absci to apply its AI technology in a new market segment, animal health, which could lead to new revenue streams and market expansion. This is likely to positively impact Absci's stock in the short term as it demonstrates innovation and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90